Previous studies have shown that pathogenic heterozygous mutations in the SMAD2 gene are implicated in distinct clinical presentations: they are a recognized cause of congenital heart defects (CHTD8) and are also associated with aneurysmal disease [21, 22]. This evidence concerns the gene SMAD2 and Vascular dilatation.